Ruxolitinib treatment of a patient with steroid-dependent severe autoimmunity due to STAT1 gain-of-function mutation
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Ruxolitinib treatment of a patient with steroid-dependent severe autoimmunity due to STAT1 gain-of-function mutation
Authors
Keywords
-
Journal
INTERNATIONAL JOURNAL OF HEMATOLOGY
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2020-03-16
DOI
10.1007/s12185-020-02860-7
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Hematopoietic stem cell transplantation in patients with gain-of-function signal transducer and activator of transcription 1 mutations
- (2018) Jennifer W. Leiding et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Ruxolitinib partially reverses functional natural killer cell deficiency in patients with signal transducer and activator of transcription 1 (STAT1) gain-of-function mutations
- (2018) Alexander Vargas-Hernández et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Utility of Ruxolitinib in a Child with Chronic Mucocutaneous Candidiasis Caused by a Novel STAT1 Gain-of-Function Mutation
- (2018) Markéta Bloomfield et al. JOURNAL OF CLINICAL IMMUNOLOGY
- Jakinibs for the treatment of immune dysregulation in patients with gain-of-function signal transducer and activator of transcription 1 (STAT1) or STAT3 mutations
- (2018) Lisa R. Forbes et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Hematopoietic Stem Cell Transplantation in Patients with Heterozygous STAT1 Gain-of-Function Mutation
- (2018) Ayca Kiykim et al. JOURNAL OF CLINICAL IMMUNOLOGY
- Ruxolitinib reverses dysregulated T helper cell responses and controls autoimmunity caused by a novel signal transducer and activator of transcription 1 (STAT1) gain-of-function mutation
- (2017) Katja G. Weinacht et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Multicolor Flow Cytometry for the Diagnosis of Primary Immunodeficiency Diseases
- (2017) Takehiro Takashima et al. JOURNAL OF CLINICAL IMMUNOLOGY
- Heterozygous STAT1 gain-of-function mutations underlie an unexpectedly broad clinical phenotype
- (2016) J. Toubiana et al. BLOOD
- Ruxolitinib Induces Interleukin 17 and Ameliorates Chronic Mucocutaneous Candidiasis Caused by STAT1 Gain-of-Function Mutation
- (2016) Rotraut Mössner et al. CLINICAL INFECTIOUS DISEASES
- Use of ruxolitinib to successfully treat chronic mucocutaneous candidiasis caused by gain-of-function signal transducer and activator of transcription 1 (STAT1) mutation
- (2015) Eleanor Higgins et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Dominant gain-of-function STAT1 mutations in FOXP3 wild-type immune dysregulation–polyendocrinopathy–enteropathy–X-linked–like syndrome
- (2013) Gulbu Uzel et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- A 1-Year-Old Girl with a Gain-of-Function STAT1 Mutation Treated with Hematopoietic Stem Cell Transplantation
- (2013) Juan Carlos Aldave et al. JOURNAL OF CLINICAL IMMUNOLOGY
- Gain-of-function humanSTAT1mutations impair IL-17 immunity and underlie chronic mucocutaneous candidiasis
- (2011) Luyan Liu et al. JOURNAL OF EXPERIMENTAL MEDICINE
- STAT1Mutations in Autosomal Dominant Chronic Mucocutaneous Candidiasis
- (2011) Frank L. van de Veerdonk et al. NEW ENGLAND JOURNAL OF MEDICINE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started